CSA Medical Secures $23 Million to Advance its Cryospray(TM) Therapies for Esophageal Disease and COPD

Financing to Support Expansion of CSA's truFreeze® Spray Cryotherapy Business for Esophageal Disease and Launch of the Reo Radial Catheter in 2019 for Barrett's Esophagus Also Supports CE Mark and Pivotal Clinical Study Launch for RejuvenAir® Sp... Devices, Venture Capital CSA Medical, Cryospray, RejuvenAir, Esophageal Disease, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news